AbbVie’s Elahere gets CHMP nod as competition advances

As competition comes for AbbVie’s FOLR1-targeting ADC Elahere in ovarian cancer, EMA’s CHMP issued positive opinion for the therapy. At its September meeting, the committee also recommended approval four other new therapies and label expansions for at least 10. AbbVie and Roche withdrew applications.

The CHMP recommendation for Elahere mirvetuximab soravtansine from AbbVie Inc. (NYSE:ABBV) is for use of the antibody-drug conjugate (ADC) to treat FOLR1-positive epithelial ovarian, fallopian tube and primary peritoneal cancer. In April, FDA granted the product full approval for a similar set of indications, converting its 2022 accelerated approval. ...